GAMMA Investing LLC raised its stake in shares of DaVita Inc. (NYSE:DVA – Free Report) by 20.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,587 shares of the company’s stock after purchasing an additional 272 shares during the period. GAMMA Investing LLC’s holdings in DaVita were worth $237,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Transcendent Capital Group LLC purchased a new position in shares of DaVita in the 3rd quarter worth $25,000. Blue Trust Inc. raised its holdings in shares of DaVita by 56.4% in the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after purchasing an additional 119 shares during the period. Quarry LP acquired a new position in shares of DaVita in the 3rd quarter valued at about $60,000. Point72 Hong Kong Ltd purchased a new stake in shares of DaVita during the 2nd quarter worth about $68,000. Finally, Versant Capital Management Inc increased its position in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after purchasing an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.
DaVita Stock Performance
DaVita stock opened at $152.73 on Wednesday. DaVita Inc. has a 12-month low of $103.40 and a 12-month high of $169.51. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The company has a market capitalization of $12.52 billion, a price-to-earnings ratio of 16.48, a price-to-earnings-growth ratio of 0.86 and a beta of 0.92. The firm’s fifty day moving average price is $154.88 and its 200 day moving average price is $151.87.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on DVA shares. Truist Financial boosted their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Barclays increased their price target on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $161.80.
View Our Latest Research Report on DaVita
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
- Five stocks we like better than DaVita
- Insider Trading – What You Need to Know
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- 3 Dividend Kings To Consider
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Overbought Stocks Explained: Should You Trade Them?
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.